| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Verona Pharma plc | 7,503,976 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | Verona Pharma plc | 3,866,214 | 4.8% | EDGAR |
| SC 13G | 2024-02-09 | FMR LLC | Verona Pharma plc | 39,219,016 | 6.2% | EDGAR |
| SC 13G | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Verona Pharma plc | 30,271,952 | 4.7% | EDGAR |
| SC 13D/A | 2023-05-16 | ORBIMED ADVISORS LLC | Verona Pharma plc | 3,777,778 | 4.8% | EDGAR |
| SC 13G/A | 2023-04-25 | Access Industries Holdings LLC | Verona Pharma plc | 0 | 0.0% | EDGAR |
| SC 13G | 2023-04-20 | PERCEPTIVE ADVISORS LLC | Verona Pharma plc | 4,462,666 | 5.6% | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | Verona Pharma plc | 7,691,990 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | VIVO VENTURES VII, LLC | Verona Pharma plc | 23,142,200 | 3.8% | EDGAR |
| SC 13G/A | 2023-02-09 | Access Industries Holdings LLC | Verona Pharma plc | 32,946,296 | 5.4% | EDGAR |
| SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Verona Pharma plc | 26,770,960 | 4.4% | EDGAR |
| SC 13D/A | 2022-12-27 | ORBIMED ADVISORS LLC | Verona Pharma plc | 4,260,691 | 5.6% | EDGAR |
| SC 13D/A | 2022-09-07 | Growth Equity Opportunities Fund IV, LLC | Verona Pharma plc | 46,447,651 | 7.9% | EDGAR |
| SC 13D/A | 2022-08-12 | ORBIMED ADVISORS LLC | Verona Pharma plc | 5,028,174 | 6.9% | EDGAR |
| SC 13D/A | 2022-08-11 | Abingworth LLP | Verona Pharma plc | 21,313,822 | 4.4% | EDGAR |
| SC 13G/A | 2022-08-10 | Access Industries Holdings LLC | Verona Pharma plc | 51,111,648 | 10.5% | EDGAR |
| SC 13G/A | 2022-02-14 | RA CAPITAL MANAGEMENT, L.P. | Verona Pharma plc | 48,778,172 | 10.0% | EDGAR |
| SC 13G/A | 2022-02-11 | Vivo Ventures VI, LLC | Verona Pharma plc | 0 | 0.0% | EDGAR |
| SC 13G | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Verona Pharma plc | 38,655,904 | 8.3% | EDGAR |
| SC 13G | 2021-02-16 | RA CAPITAL MANAGEMENT, L.P. | Verona Pharma plc | 41,543,004 | 10.0% | EDGAR |